Amid buzz around a short sell­er’s FBI vis­it, MiMedx stock craters fol­low­ing in­ter­nal in­ves­ti­ga­tion

A bio­phar­ma in Geor­gia tied to an un­usu­al FBI sto­ry is watch­ing its stock tum­ble this morn­ing fol­low­ing news that the com­pa­ny is launch­ing an in­ves­ti­ga­tion in­to its own prac­tices.

The com­pa­ny, called MiMedx $MDXG, has been in­volved in a nasty re­la­tion­ship with short sell­ers that re­cent­ly took a turn for the worse. Now, the com­pa­ny’s in­ter­nal in­ves­ti­ga­tion is de­lay­ing the re­lease of its fi­nan­cial re­sults, in­clud­ing its an­nu­al state­ment that would de­tail last year’s per­for­mance.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.